379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

医学 内科学 耐受性 肿瘤科 不利影响 胃肠病学
作者
Peter Schmid,Piotr J. Wysocki,X. Cynthia,Y.H. Park,Renan Fernandes,Simon Lord,Richard D. Baird,Catherine Prady,Kyung Hae Jung,Jamil Asselah,Robert Huisden,Ross Stewart,K. Heider,Petra Vuković,Neelima Denduluri,Zbigniew Nowecki
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S337-S337 被引量:44
标识
DOI:10.1016/j.annonc.2023.09.556
摘要

BEGONIA (NCT03742102) is an ongoing 2-part, open-label platform study in 1L a/mTNBC, evaluating D, an anti–PD-L1 antibody, plus novel therapies, including Dato-DXd, an antibody-drug conjugate made of a anti-TROP2 antibody covalently linked via a cleavable linker to a topoisomerase I inhibitor payload. Early data from BEGONIA Arm 7, Dato-DXd + D, showed promising responses. Updated results, including response duration (DoR), are reported. Patients (pts) with unresectable a/mTNBC eligible for 1L treatment were enrolled, regardless of PD-L1/TROP2 expression, and received Dato-DXd 6 mg/kg IV + D 1120 mg IV Q3W until progression or unacceptable toxicity. PD-L1, assessed by the VENTANA PD-L1 (SP263) Assay, was high if ≥10% of the tumor area was populated by PD-L1–expressing tumor or immune cells. Primary endpoints were safety and tolerability. Secondary endpoints included investigator-assessed ORR, PFS (RECIST v1.1), and DoR. As of 2 Feb 2023, 62 pts received Dato-DXd + D (29 ongoing). Median follow-up was 11.7 (range 2–20) months (mos). At baseline, median pt age was 53 years; 60% had visceral metastases; 87% had PD-L1–low expression. Confirmed ORR was 79% (95% CI, 67–88); 6 (10%) pts had complete and 43 (69%) had partial responses. Response to treatment was irrespective of PD-L1 expression level. Median DoR was 15.5 mos (95% CI, 9.9–not calculable [NC]). Median PFS was 13.8 mos (95% CI, 11–NC). Nausea and stomatitis were the most common adverse events (AEs; 40 [65%] each). Any Grade (G) 3/4 AEs occurred in 35 (57%) pts and serious AEs in 14 (23%). Low rates of anemia (9 [15%]), diarrhea (8 [13%]), and neutropenia (3 [5%]) occurred. Adjudicated treatment-related interstitial lung disease/pneumonitis occurred in 3 (5%) pts (2 G2; 1 G1). No deaths due to treatment-related AEs occurred. 10 (16%) pts discontinued any study drug due to AEs. No new safety signals were reported. Dato-DXd combined with D continues to demonstrate manageable safety and compelling high, durable response rates in 1L a/mTNBC. Further investigation is warranted. Translational data analysis is ongoing. Funding: AstraZeneca/Daiichi Sankyo.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
明亮剑完成签到,获得积分10
刚刚
小六发布了新的文献求助10
1秒前
完美世界的应助被海盗船长采纳,获得10
1秒前
1秒前
mm完成签到,获得积分10
2秒前
欢呼宛秋完成签到,获得积分10
2秒前
李爱国的应助被falleesheep采纳,获得10
3秒前
3秒前
4秒前
风吹麦浪的应助被麻瓜采纳,获得10
4秒前
张琦123456完成签到,获得积分20
4秒前
5秒前
5秒前
6秒前
HotWire99发布了新的文献求助10
7秒前
隐形曼青的应助被杜若时采纳,获得10
7秒前
7秒前
lx发布了新的文献求助10
7秒前
keyandaizi完成签到,获得积分10
7秒前
dde发布了新的文献求助10
7秒前
7秒前
betterme完成签到,获得积分10
8秒前
航宇完成签到,获得积分10
8秒前
8秒前
dian完成签到,获得积分20
9秒前
小马甲的应助被小六采纳,获得30
9秒前
怡然的剑发布了新的文献求助10
10秒前
12秒前
xiaotu发布了新的文献求助10
12秒前
服惹id发布了新的文献求助10
12秒前
13秒前
于音发布了新的文献求助30
14秒前
炸炸炸发布了新的文献求助10
14秒前
14秒前
14秒前
journey完成签到,获得积分10
15秒前
张伟发布了新的文献求助10
15秒前
思源的应助被26采纳,获得10
16秒前
无昵称完成签到,获得积分10
17秒前
心想事成完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191545
求助须知:如何正确求助?哪些是违规求助? 9578288
关于积分的说明 21858500
捐赠科研通 7790850
什么是DOI,文献DOI怎么找? 3436651
关于科研通互助平台的介绍 2560362
邀请新用户注册赠送积分活动 2483429